• Explore /
  • Poster
  • / Ramucirumab beyond progression plus TAS 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab-based therapy: Final results of the phase II RE-ExPEL study.

Ramucirumab beyond progression plus TAS 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab-based therapy: Final results of the phase II RE-ExPEL study.

Abstract Video & Slides Poster

Authors

null

Thorsten Oliver Goetze

Institut für Klinische Krebsforschung IKF am Krankenhaus Nordwest, and Krankenhaus Nordwest, University Cancer Center, Frankfurt, Germany;

Thorsten Oliver Goetze , Alexander Stein , Sylvie Lorenzen , Timorshah Habibzada , Eray Goekkurt , Peter Herhaus , Disorn Sookthai , Kristina Ihrig , Claudia Pauligk , Salah-Eddin Al-Batran

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04517747

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 359)

DOI

10.1200/JCO.2023.41.4_suppl.359

Abstract #

359

Poster Bd #

E20

Abstract Disclosures

Similar Posters

First Author: Sylvie Lorenzen

First Author: Rutika Mehta

First Author: Timothy Jay Price

First Author: Rutika Mehta